Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doravirine/Islatravir switch study in virologically suppressed HIV-1 patients
NCT05630755Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus type 1 infection (HIV-1) comparing DOR/ISL + Placebo with BIC/FTC/TAF + Placebo (2 arms). Primary endpoints: Percentage of Participants With HIV-1 RNA ≥50 copies/mL at 48 weeks, Adverse Events at 48 weeks and 1 more. Started Feb 2023; status: active, not recruiting.
02
Drugs
doravirine + islatravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05630755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05630755.